- Joined
- 27 June 2010
- Posts
- 4,139
- Reactions
- 308
Lumos Diagnostics is a fully integrated developer and manufacturer of rapid, point-of-care (POC) diagnostic solutions. Lumos' capabilities and technologies allow it to take a POC diagnostic test from the early stage of developing an initial product concept, through development, clinical validation and verification, and then to manufacture of the test at commercial scale.
Lumos develops and manufactures proprietary and in-licensed POC diagnostic tests for commercial sale through distributors under its Products division, and develops and manufactures POC diagnostic tests on behalf of clients under fee-based commercial contracts under its Commercial Services division.
In FY20, Lumos launched FebriDx®, a POC diagnostic test that is able to rapidly identify patients with a microbial infection and, if positive, determine if that infection is caused by a virus or bacteria. Lumos has already appointed distributors and commenced initial commercial sales of FebriDx® in target markets including the United Kingdom, Germany and Canada. An initial 510(k) submission for regulatory clearance for FebriDx® in the United States is currently under review with the US Food and Drug Administration (FDA) for the use of FebriDx® to differentiate viral from bacterial infection in patients with acute respiratory infections. Subject to approval from the FDA for FebriDx®, Lumos intends to launch the product into the United States market.
It is anticipated that LDX will list on the ASX during June 2021.
lumosdiagnostics.com
Lumos develops and manufactures proprietary and in-licensed POC diagnostic tests for commercial sale through distributors under its Products division, and develops and manufactures POC diagnostic tests on behalf of clients under fee-based commercial contracts under its Commercial Services division.
In FY20, Lumos launched FebriDx®, a POC diagnostic test that is able to rapidly identify patients with a microbial infection and, if positive, determine if that infection is caused by a virus or bacteria. Lumos has already appointed distributors and commenced initial commercial sales of FebriDx® in target markets including the United Kingdom, Germany and Canada. An initial 510(k) submission for regulatory clearance for FebriDx® in the United States is currently under review with the US Food and Drug Administration (FDA) for the use of FebriDx® to differentiate viral from bacterial infection in patients with acute respiratory infections. Subject to approval from the FDA for FebriDx®, Lumos intends to launch the product into the United States market.
It is anticipated that LDX will list on the ASX during June 2021.
Welcome to Lumos Diagnostics
Lumos Diagnostics specializes in rapid, cost-effective point-of-care diagnostic test solutions. Learn about our team, products, services, investment opportunities, latest news, and how we innovate at the point-of-care.
lumosdiagnostics.com
